pharmaceuticals($5 billion revenue)
provider of injectable drugs and infusion technologies
to gain greater detailed performance insights into the operating network to determine if there is a better approach for servicing customers
I continue to be impressed by the system.
John Elliot • Senior Vice President of Operations • Hospira
network optimization &
\descriptive • diagnostic • prescriptive analytics
supply chain • finance • sales
data governance • cross-functional agreement on detailed performance information • tracking ongoing performance
- $20 million
savings opportunity identified
for SKU-level strategies
- data refreshing
revelaed profit opportunities that can be tracked
use of profit insights
The results illustrated in this case study are specific to the particular situations, business models, data input, and computing environments described herein. Each Competitive Insights (CI) customer’s experience is unique based on business and technical variables and all statements must be considered non-typical. Actual savings, results, and performance characteristics will vary depending on individual customer configurations and conditions. CI does not guarantee or represent that every customer will achieve similar results.